Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. reports developments in women's health and family building benefits, including fertility care access, employer demand, product expansion, and financial results. The company provides benefit solutions for employers, health plans, and benefit purchasers, combining concierge support, coaching, education, digital tools, and access to a network of fertility and women's health specialists.
Recurring updates include quarterly earnings, financial guidance, selling-season activity, share repurchases, investor conference appearances, and offerings such as Progyny Select, a fully insured supplemental fertility and family building plan for small U.S. employers.
Progyny (Nasdaq: PGNY), a leader in fertility benefits management, announced its executives will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 11:40 A.M. ET. The event will provide insights into their comprehensive fertility solutions aimed at improving patient care and reducing costs for employers. A live audiocast and replay will be available on Progyny's website. The company is noted for its innovative approach and recognition from various organizations, indicating its growth and leadership in the industry.
Progyny, Inc. (Nasdaq: PGNY) will release its financial results for Q1 2022 on May 5, 2022, after market close. A conference call will follow at 4:45 PM Eastern Time. Interested parties can join via phone or through a live webcast available on the company’s investor relations page. Progyny specializes in fertility benefits management, offering comprehensive solutions that enhance patient care while reducing employer healthcare costs. The company has gained recognition for its innovative approach and commitment to improving fertility solutions across the U.S.
Progyny, Inc. (PGNY) and RESOLVE: The National Infertility Association are set to highlight National Infertility Awareness Week 2022 by ringing the Nasdaq Opening Bell on April 26, 2022, and lighting the Empire State Building in orange on April 27, 2022. This initiative aims to raise awareness about infertility, affecting 1 in 8 couples in the U.S. CEO Pete Anevski emphasized Progyny's mission to support over 100,000 individuals in their family building journeys. The event seeks to eliminate stigmas associated with infertility and calls on employers and legislators to address the crisis.
Progyny (Nasdaq: PGNY), a top benefits management company in fertility and family building solutions, announced that CEO Pete Anevski and CFO Mark Livingston will engage in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2022, at 3:50 P.M. ET. This event aims to discuss Progyny's innovative approach to fertility benefits, highlighting its comprehensive solutions that benefit employers, patients, and physicians. A live audiocast and replay will be accessible on their official website.
Progyny, Inc. (PGNY) reported record revenues of $500.6 million for 2021, marking a 45% growth year-over-year. The fourth quarter revenue reached $127.6 million, up 27%, driven by a significant increase in clients. Despite the impact of the COVID-19 Omicron variant, the company maintained a high retention rate and successful sales season. However, net income in Q4 decreased to $15.1 million from $39.1 million the previous year, primarily due to a lower tax benefit. Looking ahead, 2022 guidance forecasts revenue of $730 million to $775 million, reflecting 46% to 55% growth.
Progyny, Inc. (Nasdaq: PGNY) will announce its financial results for the quarterly period and full year ending December 31, 2021, on February 28, 2022. A conference call will be held at 4:45 PM ET to discuss the results, with access details provided for U.S. and international participants. An audio replay will be available until March 7, 2022. Progyny specializes in fertility and family building benefits, focusing on education and access to specialists while reducing costs for employers. The company has received recognition for its growth and leadership in the sector.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, announced its CEO, Pete Anevski, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 A.M. ET. The presentation will be followed by a breakout session featuring President Michael Sturmer and CFO Mark Livingston. A live audiocast and replay will be accessible on Progyny's website. Progyny is recognized for its innovative fertility solutions that benefit patients, employers, and healthcare providers alike.
Progyny (PGNY) reported a strong third quarter of 2021, with revenues of $122.3 million, marking a 24% increase year-over-year. The company added over 85 new clients, resulting in approximately 1.2 million new covered lives. Gross profit rose to $28.5 million with a gross margin of 23.3%, up from 21.1% in the previous year. Net income reached $16.8 million, a significant increase from $4.8 million last year. For 2022, Progyny anticipates revenue growth of about 50%, driven by new client launches.
Progyny, Inc. (Nasdaq: PGNY) is set to release its financial results for the quarter ending September 30, 2021, on November 4, 2021, after market close. A conference call will follow at 4:45 PM ET, during which the company will discuss its results. Participants can join by dialing the provided numbers. An audio replay will be available until November 11, 2021. Progyny specializes in fertility and family-building benefits, focusing on comprehensive solutions that benefit employers, patients, and healthcare providers.
Progyny, a leader in fertility benefits management, announced that CEO David Schlanger and CFO Mark Livingston will participate in a fireside chat at the BofA Global Healthcare Conference on September 15, 2021, at 10:55 A.M. ET. The event will be accessible via a live audiocast on Progyny’s website. Progyny aims to redefine fertility and family building benefits, enhancing access to comprehensive care and reducing healthcare costs for employers. The company has received multiple recognitions for its growth and leadership.